Voss Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Voss Capital’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-125,000	Closed	-$2.63M	–	67
2025 Q4	$2.63M	Buy	+125,000	New	+$2.18M	0.13%	49

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Voss Capital's SNDX Position: Q1 2026 in Review

Voss Capital sold out of Syndax Pharmaceuticals (SNDX) in Q1 2026, closing a stake of 125,000 shares — an estimated $2.63M sold.

Voss Capital first reported a position in SNDX in Q4 2025 and held it in 1 quarter. The position peaked at $2.63M in Q4 2025. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

Voss Capital reported no remaining Syndax Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Voss Capital sold 125,000 Syndax Pharmaceuticals shares in Q1 2026, an estimated $2.63M.
Voss Capital first reported a position in Syndax Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Voss Capital's Syndax Pharmaceuticals position peaked at $2.63M in Q4 2025.
246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Voss Capital's 13F filing for Q1 2026, filed 15 May 2026.